Catalent (NYSE:CTLT) had its target price lifted by equities research analysts at Bank of America from $47.00 to $49.00 in a research report issued to clients and investors on Tuesday, February 6th, Marketbeat reports. The firm presently has a “buy” rating on the stock. Bank of America’s target price would suggest a potential upside of 20.07% from the company’s current price.
Other research analysts have also recently issued reports about the company. Royal Bank of Canada set a $48.00 price target on Catalent and gave the company a “buy” rating in a research report on Monday, February 5th. Stephens cut Catalent from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 6th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a research report on Monday, November 6th. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, Goldman Sachs Group began coverage on Catalent in a research report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $45.60.
Shares of Catalent (NYSE:CTLT) traded up $0.19 during mid-day trading on Tuesday, reaching $40.81. The company had a trading volume of 1,169,082 shares, compared to its average volume of 981,623. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. The stock has a market capitalization of $5,395.41, a PE ratio of 71.60, a P/E/G ratio of 2.32 and a beta of 1.47. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in shares of Catalent by 111.5% in the second quarter. PNC Financial Services Group Inc. now owns 12,838 shares of the company’s stock worth $451,000 after acquiring an additional 6,768 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of Catalent by 2.2% in the second quarter. California Public Employees Retirement System now owns 200,800 shares of the company’s stock worth $7,048,000 after acquiring an additional 4,400 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of Catalent by 1.3% in the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Catalent in the second quarter worth approximately $23,092,000. Finally, Numeric Investors LLC acquired a new stake in shares of Catalent in the second quarter worth approximately $1,288,000. Institutional investors and hedge funds own 99.82% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/06/catalent-ctlt-given-new-49-00-price-target-at-bank-of-america.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.